Global Bronchiectasis Treatment

Bronchiectasis Treatment Comprehensive Study by Application (Clinics, Hospital, Homecare), Treatment (Medication, Exercises, Devices, Surgery), Bronchiectasis (Cylindrical Bronchiectasis, Varicose Bronchiectasis, Saccular or Cystic Bronchiectasis) Players and Region - Global Market Outlook to 2027

Bronchiectasis Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Bronchiectasis Treatment?
The bronchiectasis treatment is a chronic condition of lungs, known as the abnormal, irreversible dilation of the bronchi where the muscular tissue and elastic tissue is destroyed by chronic or acute inflammation and infection. This damage done to the lungs impairs the natural drainage of bronchial secretion leading to airway obstruction, if not checked it can result in progressive lung damage. The aim of the treatment is to improve the symptoms complications, to control exacerbations, and to reduce morbidity and mortality. The use of intravenous immunoglobulin or intravenous alpha1-antitrypsin (AAT) therapy, is essential to the overall treatment.

The market study is broken down, by Application (Clinics, Hospital and Homecare) and major geographies with country level break-up.

Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Bronchiectasis Treatment market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

SmartVest (Electromed, Inc.) (United States), Aradigm Corporation (United States), Koninklijke Philips N.V., (Netherlands), Insmed, Inc. (United States), Bayer AG (Germany), Zambon (Italy), AirPhysio (Australia), AffloVest (Independence Plus, Inc.) (United States) and Alitair Pharmaceuticals (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Bronchiectasis Treatment market by Type, Application and Region.

On the basis of geography, the market of Bronchiectasis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medication will boost the Bronchiectasis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Bronchiectasis, the sub-segment i.e. Cylindrical Bronchiectasis will boost the Bronchiectasis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 29th August 2019, Electromed entered into the agreement with two home medical equipment distributors to enhance the distribution of and provide the facility of access to its SmartVest Airway Clearance System people with bronchiectasis problems, respiratory problems, chronic obstructive pulmonary disease, and cystic fibrosis, in the United States. The product has been designed to deliver high-frequency chest oscillation (HFCWO) therapy that uses rapid pulses that squeeze the abdomen and upper body.
On 27th June 2019, Electromed Inc. announced the result of a clinical study on first of its kind study published in BMC Pulmonary Medicine found that the use of the SmartVest Airway Clearance System as a part of the treatment algorithm significantly decreased exacerbations requiring hospitalization and antibiotic use among non-CF bronchiectasis patients.


Market Trend
  • The prevalent occurrence of severe cystic bronchiectasis treatment has decreased over the period of time because of the adoption of vaccination against childhood infections. The more advanced availability of antibiotics and treatment is on research.

Market Drivers
  • More Frequent Occurance of Bronchiectasis Diseases in Less Affluent Communities and in Indigenous Communities
  • Prevalence of Bronchiectasis Diseases in Patients Over 60 Years of Age

Opportunities
  • Treatment Infrastructure Investment will Boost the Bronchiectasis Treatment
  • Raising Awareness about the Bronchiectasis Treatment and its Benefits

Restraints
  • In Certain Parts of the World with Poor Health and Less Socio-Economic Conditions, the Bronchiectasis Treatment is Still Common
  • Risk of Complications with Bronchiectasis Treatment

Challenges
  • High Treatment Cost and Ignorance While Diagnosing Might be the Hindrance for Bronchiectasis Treatment Market


Key Target Audience
Bronchiectasis Treatment Drugs Manufacturers, Bronchiectasis Treatment Devices Manufacturers, Bronchiectasis Treatment International Traders, Bronchiectasis Treatment Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Clinics
  • Hospital
  • Homecare
By Treatment
  • Medication
  • Exercises
  • Devices
  • Surgery

By Bronchiectasis
  • Cylindrical Bronchiectasis
  • Varicose Bronchiectasis
  • Saccular or Cystic Bronchiectasis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. More Frequent Occurance of Bronchiectasis Diseases in Less Affluent Communities and in Indigenous Communities
      • 3.2.2. Prevalence of Bronchiectasis Diseases in Patients Over 60 Years of Age
    • 3.3. Market Challenges
      • 3.3.1. High Treatment Cost and Ignorance While Diagnosing Might be the Hindrance for Bronchiectasis Treatment Market
    • 3.4. Market Trends
      • 3.4.1. The prevalent occurrence of severe cystic bronchiectasis treatment has decreased over the period of time because of the adoption of vaccination against childhood infections. The more advanced availability of antibiotics and treatment is on research.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bronchiectasis Treatment, by Application, Treatment, Bronchiectasis and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Bronchiectasis Treatment (Value)
      • 5.2.1. Global Bronchiectasis Treatment by: Application (Value)
        • 5.2.1.1. Clinics
        • 5.2.1.2. Hospital
        • 5.2.1.3. Homecare
      • 5.2.2. Global Bronchiectasis Treatment by: Treatment (Value)
        • 5.2.2.1. Medication
        • 5.2.2.2. Exercises
        • 5.2.2.3. Devices
        • 5.2.2.4. Surgery
      • 5.2.3. Global Bronchiectasis Treatment by: Bronchiectasis (Value)
        • 5.2.3.1. Cylindrical Bronchiectasis
        • 5.2.3.2. Varicose Bronchiectasis
        • 5.2.3.3. Saccular or Cystic Bronchiectasis
      • 5.2.4. Global Bronchiectasis Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Bronchiectasis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. SmartVest (Electromed, Inc.) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aradigm Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Koninklijke Philips N.V., (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Insmed, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Zambon (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AirPhysio (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AffloVest (Independence Plus, Inc.) (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alitair Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Bronchiectasis Treatment Sale, by Application, Treatment, Bronchiectasis and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Bronchiectasis Treatment (Value)
      • 7.2.1. Global Bronchiectasis Treatment by: Application (Value)
        • 7.2.1.1. Clinics
        • 7.2.1.2. Hospital
        • 7.2.1.3. Homecare
      • 7.2.2. Global Bronchiectasis Treatment by: Treatment (Value)
        • 7.2.2.1. Medication
        • 7.2.2.2. Exercises
        • 7.2.2.3. Devices
        • 7.2.2.4. Surgery
      • 7.2.3. Global Bronchiectasis Treatment by: Bronchiectasis (Value)
        • 7.2.3.1. Cylindrical Bronchiectasis
        • 7.2.3.2. Varicose Bronchiectasis
        • 7.2.3.3. Saccular or Cystic Bronchiectasis
      • 7.2.4. Global Bronchiectasis Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bronchiectasis Treatment: by Application(USD Million)
  • Table 2. Bronchiectasis Treatment Clinics , by Region USD Million (2016-2021)
  • Table 3. Bronchiectasis Treatment Hospital , by Region USD Million (2016-2021)
  • Table 4. Bronchiectasis Treatment Homecare , by Region USD Million (2016-2021)
  • Table 5. Bronchiectasis Treatment: by Treatment(USD Million)
  • Table 6. Bronchiectasis Treatment Medication , by Region USD Million (2016-2021)
  • Table 7. Bronchiectasis Treatment Exercises , by Region USD Million (2016-2021)
  • Table 8. Bronchiectasis Treatment Devices , by Region USD Million (2016-2021)
  • Table 9. Bronchiectasis Treatment Surgery , by Region USD Million (2016-2021)
  • Table 10. Bronchiectasis Treatment: by Bronchiectasis(USD Million)
  • Table 11. Bronchiectasis Treatment Cylindrical Bronchiectasis , by Region USD Million (2016-2021)
  • Table 12. Bronchiectasis Treatment Varicose Bronchiectasis , by Region USD Million (2016-2021)
  • Table 13. Bronchiectasis Treatment Saccular or Cystic Bronchiectasis , by Region USD Million (2016-2021)
  • Table 14. South America Bronchiectasis Treatment, by Country USD Million (2016-2021)
  • Table 15. South America Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 16. South America Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 17. South America Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 18. Brazil Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 19. Brazil Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 20. Brazil Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 21. Argentina Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 22. Argentina Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 23. Argentina Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 24. Rest of South America Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 25. Rest of South America Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 26. Rest of South America Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 27. Asia Pacific Bronchiectasis Treatment, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 29. Asia Pacific Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 30. Asia Pacific Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 31. China Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 32. China Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 33. China Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 34. Japan Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 35. Japan Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 36. Japan Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 37. India Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 38. India Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 39. India Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 40. South Korea Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 41. South Korea Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 42. South Korea Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 43. Taiwan Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 44. Taiwan Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 45. Taiwan Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 46. Australia Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 47. Australia Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 48. Australia Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 52. Europe Bronchiectasis Treatment, by Country USD Million (2016-2021)
  • Table 53. Europe Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 54. Europe Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 55. Europe Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 56. Germany Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 57. Germany Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 58. Germany Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 59. France Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 60. France Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 61. France Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 62. Italy Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 63. Italy Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 64. Italy Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 65. United Kingdom Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 66. United Kingdom Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 67. United Kingdom Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 68. Netherlands Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 69. Netherlands Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 70. Netherlands Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 71. Rest of Europe Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 72. Rest of Europe Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 73. Rest of Europe Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 74. MEA Bronchiectasis Treatment, by Country USD Million (2016-2021)
  • Table 75. MEA Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 76. MEA Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 77. MEA Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 78. Middle East Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 79. Middle East Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 80. Middle East Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 81. Africa Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 82. Africa Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 83. Africa Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 84. North America Bronchiectasis Treatment, by Country USD Million (2016-2021)
  • Table 85. North America Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 86. North America Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 87. North America Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 88. United States Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 89. United States Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 90. United States Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 91. Canada Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 92. Canada Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 93. Canada Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 94. Mexico Bronchiectasis Treatment, by Application USD Million (2016-2021)
  • Table 95. Mexico Bronchiectasis Treatment, by Treatment USD Million (2016-2021)
  • Table 96. Mexico Bronchiectasis Treatment, by Bronchiectasis USD Million (2016-2021)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Bronchiectasis Treatment: by Application(USD Million)
  • Table 107. Bronchiectasis Treatment Clinics , by Region USD Million (2022-2027)
  • Table 108. Bronchiectasis Treatment Hospital , by Region USD Million (2022-2027)
  • Table 109. Bronchiectasis Treatment Homecare , by Region USD Million (2022-2027)
  • Table 110. Bronchiectasis Treatment: by Treatment(USD Million)
  • Table 111. Bronchiectasis Treatment Medication , by Region USD Million (2022-2027)
  • Table 112. Bronchiectasis Treatment Exercises , by Region USD Million (2022-2027)
  • Table 113. Bronchiectasis Treatment Devices , by Region USD Million (2022-2027)
  • Table 114. Bronchiectasis Treatment Surgery , by Region USD Million (2022-2027)
  • Table 115. Bronchiectasis Treatment: by Bronchiectasis(USD Million)
  • Table 116. Bronchiectasis Treatment Cylindrical Bronchiectasis , by Region USD Million (2022-2027)
  • Table 117. Bronchiectasis Treatment Varicose Bronchiectasis , by Region USD Million (2022-2027)
  • Table 118. Bronchiectasis Treatment Saccular or Cystic Bronchiectasis , by Region USD Million (2022-2027)
  • Table 119. South America Bronchiectasis Treatment, by Country USD Million (2022-2027)
  • Table 120. South America Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 121. South America Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 122. South America Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 123. Brazil Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 124. Brazil Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 125. Brazil Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 126. Argentina Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 127. Argentina Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 128. Argentina Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 129. Rest of South America Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 130. Rest of South America Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 131. Rest of South America Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 132. Asia Pacific Bronchiectasis Treatment, by Country USD Million (2022-2027)
  • Table 133. Asia Pacific Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 134. Asia Pacific Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 135. Asia Pacific Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 136. China Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 137. China Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 138. China Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 139. Japan Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 140. Japan Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 141. Japan Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 142. India Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 143. India Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 144. India Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 145. South Korea Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 146. South Korea Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 147. South Korea Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 148. Taiwan Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 149. Taiwan Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 150. Taiwan Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 151. Australia Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 152. Australia Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 153. Australia Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 157. Europe Bronchiectasis Treatment, by Country USD Million (2022-2027)
  • Table 158. Europe Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 159. Europe Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 160. Europe Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 161. Germany Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 162. Germany Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 163. Germany Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 164. France Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 165. France Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 166. France Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 167. Italy Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 168. Italy Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 169. Italy Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 170. United Kingdom Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 171. United Kingdom Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 172. United Kingdom Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 173. Netherlands Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 174. Netherlands Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 175. Netherlands Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 176. Rest of Europe Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 177. Rest of Europe Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 178. Rest of Europe Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 179. MEA Bronchiectasis Treatment, by Country USD Million (2022-2027)
  • Table 180. MEA Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 181. MEA Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 182. MEA Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 183. Middle East Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 184. Middle East Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 185. Middle East Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 186. Africa Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 187. Africa Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 188. Africa Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 189. North America Bronchiectasis Treatment, by Country USD Million (2022-2027)
  • Table 190. North America Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 191. North America Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 192. North America Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 193. United States Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 194. United States Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 195. United States Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 196. Canada Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 197. Canada Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 198. Canada Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 199. Mexico Bronchiectasis Treatment, by Application USD Million (2022-2027)
  • Table 200. Mexico Bronchiectasis Treatment, by Treatment USD Million (2022-2027)
  • Table 201. Mexico Bronchiectasis Treatment, by Bronchiectasis USD Million (2022-2027)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bronchiectasis Treatment: by Application USD Million (2016-2021)
  • Figure 5. Global Bronchiectasis Treatment: by Treatment USD Million (2016-2021)
  • Figure 6. Global Bronchiectasis Treatment: by Bronchiectasis USD Million (2016-2021)
  • Figure 7. South America Bronchiectasis Treatment Share (%), by Country
  • Figure 8. Asia Pacific Bronchiectasis Treatment Share (%), by Country
  • Figure 9. Europe Bronchiectasis Treatment Share (%), by Country
  • Figure 10. MEA Bronchiectasis Treatment Share (%), by Country
  • Figure 11. North America Bronchiectasis Treatment Share (%), by Country
  • Figure 12. Global Bronchiectasis Treatment share by Players 2021 (%)
  • Figure 13. Global Bronchiectasis Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Bronchiectasis Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. SmartVest (Electromed, Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 17. SmartVest (Electromed, Inc.) (United States) Revenue: by Geography 2021
  • Figure 18. Aradigm Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Aradigm Corporation (United States) Revenue: by Geography 2021
  • Figure 20. Koninklijke Philips N.V., (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Koninklijke Philips N.V., (Netherlands) Revenue: by Geography 2021
  • Figure 22. Insmed, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Insmed, Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 26. Zambon (Italy) Revenue, Net Income and Gross profit
  • Figure 27. Zambon (Italy) Revenue: by Geography 2021
  • Figure 28. AirPhysio (Australia) Revenue, Net Income and Gross profit
  • Figure 29. AirPhysio (Australia) Revenue: by Geography 2021
  • Figure 30. AffloVest (Independence Plus, Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 31. AffloVest (Independence Plus, Inc.) (United States) Revenue: by Geography 2021
  • Figure 32. Alitair Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Alitair Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 34. Global Bronchiectasis Treatment: by Application USD Million (2022-2027)
  • Figure 35. Global Bronchiectasis Treatment: by Treatment USD Million (2022-2027)
  • Figure 36. Global Bronchiectasis Treatment: by Bronchiectasis USD Million (2022-2027)
  • Figure 37. South America Bronchiectasis Treatment Share (%), by Country
  • Figure 38. Asia Pacific Bronchiectasis Treatment Share (%), by Country
  • Figure 39. Europe Bronchiectasis Treatment Share (%), by Country
  • Figure 40. MEA Bronchiectasis Treatment Share (%), by Country
  • Figure 41. North America Bronchiectasis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • SmartVest (Electromed, Inc.) (United States)
  • Aradigm Corporation (United States)
  • Koninklijke Philips N.V., (Netherlands)
  • Insmed, Inc. (United States)
  • Bayer AG (Germany)
  • Zambon (Italy)
  • AirPhysio (Australia)
  • AffloVest (Independence Plus, Inc.) (United States)
  • Alitair Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Feb 2022 207 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bronchiectasis Treatment Quantitative research analysis
Global Bronchiectasis Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as SmartVest (Electromed, Inc.) (United States), Aradigm Corporation (United States), Koninklijke Philips N.V., (Netherlands), Insmed, Inc. (United States), Bayer AG (Germany), Zambon (Italy), AirPhysio (Australia), AffloVest (Independence Plus, Inc.) (United States) and Alitair Pharmaceuticals (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Bronchiectasis Treatment Market to reach USD Million by 2027.

Know More About Global Bronchiectasis Treatment Report?

Have a Query? Click Here

Other Related Reports

Stoma Care/Ostomy Care and Accessories Comprehensive Study by Type (Ostomy Care Bag (System (One, Two-Piece), Usability (Drainable, Closed), Shape (Flat, Convex)), Ostomy Care Accessories (Cleansers,...
$ 3650
Ocular Drug Delivery Comprehensive Study by Application (Bacterial Conjunctivitis, Cataract Surgery, Allergic Conjunctivitis, Retinal Vein Occlusion, Bulbar Conjunctiva, Sympathetic Ophthalmia), Dise...
$ 3750
Pharmerging Comprehensive Study by Type (Pharmaceuticals, Healthcare), Distribution Channel (Hospitals, Retail Pharmacies, Online Stores, Others), Indications (Lifestyle Diseases, Cancer and Autoimmu...
$ 3800
3D Medical Printing Systems Comprehensive Study by Type (Surgical Guides, Dental Guides, Craniomaxillofacial Guides, Orthopedic Guides, Surgical Instruments, Retractors, Others), Application (Hospita...
$ 3750
Diagnostic Imaging Services Comprehensive Study by Type (X-Ray, Magnetic Resonance Imaging (MRI), Ultrasound, Radionuclide), Application (General Radiography, Dentistry, Fluoroscopy, Neurology, Ortho...
$ 3650
In-Vitro Diagnostics Products Comprehensive Study by Type (Hematology Analyzer and Reagents, Chemistry Analyzer and Reagents, Hemoglobin System), Application (Autoimmune diseases, Cardiology, Diabete...
$ 3750